Twist Bioscience Corporation

TWST

US90184D1000

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
31.54 ^USD	+1.48%		+12.84%	-14.43%

Mar. 28	Twist Bioscience Corporation Launches Pangenome Spike-in Exome Panel to Enable Advancement of Research for Diverse Populations	CI
Mar. 12	Transcript : Twist Bioscience Corporation Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 07:30 AM

Twist Bioscience Corporation Provides Revenue Guidance for the Second Quarter of Fiscal Year 2024

February 02, 2024 at 07:32 am EST

Twist Bioscience Corporation provided revenue guidance for the second quarter of fiscal year 2024. Total revenue of approximately $70 million to $71 million.

Latest news about Twist Bioscience Corporation

Twist Bioscience Corporation Launches Pangenome Spike-in Exome Panel to Enable Advancement of Research for Diverse Populations	Mar. 28	CI
Transcript : Twist Bioscience Corporation Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 07:30 AM	Mar. 12
Twist Bioscience Corporation Launches IVDR-Compliant Precision Dx Products for Whole Exome Sequencing	Mar. 05	CI
Twist Bioscience Announces Partnership With Element Biosciences, Launches Liquid Biopsy Kit	Feb. 06	MT
Twist Bioscience Corporation and Element Biosciences, Inc. Announce Collaboration to Develop Twist for Element, Exome 2.0 Plus Comprehensive Exome Spike-In Workflow for Element?s AVITI System	Feb. 06	CI
Twist Bioscience Corporation Launches cfDNA Library Preparation Kit for Liquid Biopsy Applications	Feb. 06	CI
Scotiabank Adjusts Twist Bioscience's Price Target to $43 From $30, Maintains Sector Outperform Rating	Feb. 05	MT
Twist Bioscience Corporation Unveils Differentiated Ultra High-Throughput Library Preparation Solution at AGBT	Feb. 05	CI
Sector Update: Health Care Stocks Steady Premarket Friday	Feb. 02	MT
Twist Bioscience's Fiscal Q1 Net Loss Widens, Revenue Rises; Fiscal 2024 Revenue Guidance Lifted	Feb. 02	MT
Transcript : Twist Bioscience Corporation, Q1 2024 Earnings Call, Feb 02, 2024	Feb. 02
Earnings Flash (TWST) TWIST BIOSCIENCE CORPORATION Reports Q1 Revenue $71.5M, vs. Street Est of $67.6M	Feb. 02	MT
Twist Bioscience Corporation Provides Revenue Guidance for the Second Quarter of Fiscal Year 2024	Feb. 02	CI
Twist Bioscience Corporation Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 02	CI
Twist Bioscience Corporation Updates Earnings Guidance for the Full Fiscal Year 2024	Feb. 02	CI
North American Morning Briefing : Jobs Report Tops -2-	Feb. 02	DJ
Barclays Raises Price Target on Twist Bioscience to $45 From $30, Keeps Overweight Rating	Jan. 25	MT
Twist Bioscience Corporation Expands Express Genes Rapid Synthesis Service	Jan. 24	CI
Goldman Sachs Upgrades Twist Bioscience to Buy From Neutral, Raises Price Target to $45 From $25	Jan. 18	MT
North American Morning Briefing : TSMC Results -2-	Jan. 18	DJ
Goldman Sachs Upgrades Twist Bioscience to Buy From Neutral, Price Target is $45	Jan. 17	MT
Transcript : Twist Bioscience Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 05:15 PM	Jan. 08
Twist Bioscience Names Adam Laponis Chief Financial Officer	Jan. 05	MT
Twist Bioscience Corporation Appoints Adam Laponis as Principal Financial Officer, Effective January 8, 2024	Jan. 05	CI
Twist Bioscience Appoints Adam Laponis as Chief Financial Officer	Jan. 05	CI

Chart Twist Bioscience Corporation

Duration

Period

More charts

Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that develops manufacturing synthetic DNA by writing DNA on a silicon chip. The Company leverages its technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation and antibody libraries for drug discovery and development. It has miniaturized traditional chemical DNA synthesis reactions to write over one million short pieces of DNA on each silicon chip. It offers two product lines: synthetic biology tools and NGS tools, that address different needs of its customers across a variety of applications. It offers ribonucleic acid and protein products. Its synthetic biology products include synthetic genes and gene fragments, and oligonucleotide or oligo pools.

Sector

Pharmaceuticals

Calendar

2024-05-01 - Q2 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Twist Bioscience Corporation

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

31.54 USD

Average target price

40.25 USD

Spread / Average Target

+27.62%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
TWIST BIOSCIENCE CORPORATION	-14.43%	1.82B
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
BIOMARIN PHARMACEUTICAL INC.	-16.09%	15.36B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B

Biopharmaceuticals